Latest News
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
2 May 2025 - Blue Earth Therapeutics, a UK-based developer of radiopharmaceutical therapies, on Thursday reported further progress in the development of its radio-hybrid, lutetium-labelled, PSMA targeted, investigational radioligand therapy for metas...
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
2 May 2025 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American:ARMP) announced on Thursday that it has received an additional USD4.65m of non-dilutive funding pursuant to a previously announced US Department of Defense (DoD) award.This ...
S&E bio's SNE-101 stroke therapy approved for clinical trial
2 May 2025 - S&E bio Co Ltd, a South Korea-based biotechnology company specialising in exosomal microRNA-based therapies, announced on Thursday that it has received approval from Korea's Ministry of Food and Drug Safety (MFDS) to initiate a ...
TransCode Therapeutics reports progress in metastatic cancer trial
2 May 2025 - RNA oncology company TransCode Therapeutics Inc (NASDAQ:RNAZ) on Thursday reported further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer.TTX-MC138 is a first-in-class therapeutic candidate design...
BioArctic receives SEK101.7m in royalties from Q1 Leqembi sales
1 May 2025 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Thursday that its royalties from first-quarter 2025 global sales of Leqembi (lecanemab), developed in partnership with Eisai Co Ltd (TYO:4523), totalled SEK1...